Reagan-Udall Foundation at the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)
During the ICPE conference, our Executive Director, June Wasser, will be discussing the importance of the Foundation’s IMEDS (Innovation in Medical Evidence Development and Surveillance) program, which provides a framework and entry point for private-sector entities, such as regulated industry and other researchers into FDA’s Sentinel System. Wasser will be joined by Jeffrey Brown, PhD, of Harvard Pilgrim Health Care Institute, which serves as the analytics center for IMEDS studies. Possible studies explore topics including: protocol development and assessment, validation studies using patient charts, drug utilization or effectiveness, and comparative outcomes.
ICPE brings together leaders and key experts in a wide spectrum of pharmacoepidemiology topics including pharmacovigilance, drug utilization research, comparative effectiveness reviews, and therapeutic risk management. If you would like to meet with Wasser while she is in Prague to explore opportunities through IMEDS, please contact Brianna Farr (email@example.com).